Comparative Pharmacology
Head-to-head clinical analysis: ORTHO CYCLEN 28 versus ORTHO TRI CYCLEN 21.
Head-to-head clinical analysis: ORTHO CYCLEN 28 versus ORTHO TRI CYCLEN 21.
ORTHO CYCLEN-28 vs ORTHO TRI-CYCLEN 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norgestimate. The primary mechanism is inhibition of gonadotropin secretion (FSH and LH) via negative feedback on the hypothalamic-pituitary axis, thereby suppressing ovulation. Additional effects include thickening of cervical mucus (impedes sperm penetration) and alterations in the endometrium (reduces implantation likelihood).
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.18 mg norgestimate/0.035 mg ethinyl estradiol) orally once daily for 28 days, first tablet on day 1 of menstrual cycle with 7 placebo tablets in last 7 days.
One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours; Norelgestromin (active metabolite of norgestimate): 28-52 hours. Terminal half-lives support once-daily dosing.
Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Renal (60-70% as metabolites, ~20% unchanged), Fecal (30-40% as metabolites); primarily conjugated metabolites of ethinyl estradiol and norgestimate.
Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive